RE
RENX.L
—
London Stock Exchange
Advanced Medical Equipment & Technology
Renalytix PLC
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,2B GBp
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Renalytix PLC provides AI-based diagnostic solutions for chronic kidney disease, primarily through its Pheno-Check platform, which is used in conjunction with laboratory tests to improve patient outcomes.
Business. Renalytix PLC (RENX.L) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United Kingdom and is listed on the London Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Goldman Sachs Asset Management, L.P.
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to RENX.L. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Renalytix PLC (RENX.L) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in the United Kingdom and is listed on the London Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
AI synthesis
GENERATEDRenalytix has 437,018,680 basic shares outstanding, with no dilution from potential share issuance, as the diluted share count is equal to the basic count. The company's market price is $1.80, resulting in a market capitalization of $786.6 million. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and return metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. This limits the ability to assess performance relative to the cohort median or industry benchmarks.
Renalytix's revenue concentration and geographic exposure are not disclosed in the available data. The company does not provide segment-level revenue breakdowns or geographic revenue distribution in the input data, making it difficult to evaluate diversification or exposure to specific markets.
Growth trajectory is not quantified in the input data, as no outlook numeric deltas or revenue history are provided. The absence of forward-looking guidance or historical performance data limits the ability to assess the company's growth potential.
The company is flagged for liquidity risk, as no balance-sheet inputs are available and no going-concern language is present in source documents. Dilution risk is assessed as low, with no evidence of potential share issuance or capital-raising activities in the data provided.
No recent events, such as filings or transcripts, are included in the input data to inform the company's current strategic or operational developments.
Key takeaways
- Renalytix operates in the Advanced Medical Equipment & Technology industry, focusing on AI-based diagnostics for chronic kidney disease.
- The company has no dilution risk, as the diluted share count is equal to the basic count.
- Liquidity risk could not be assessed due to missing balance-sheet data and lack of going-concern language.
- No profitability metrics or industry benchmarks are available to evaluate performance.
- Growth trajectory and revenue history are not disclosed, limiting the ability to assess future potential.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Annual
ANNUALFiled 2023-09-28
FY 2023 · Full-year highlights
Revenue $3.4M, +14,6% YoY; Operating income +26,2% YoY.
Revenue$3.4M+14,6 % YoY
Operating income-$42.4M+26,2 % YoY
Net income-$46.2M+18,5 % YoY
Free cash flow-$43.7M+20,2 % YoY
EPS—
Operating cash flow-$32.7M+28,6 % YoY
Financials
Income statement
Revenue$3.4M
Gross profit$701.0k
Operating income-$42.4M
Net income-$46.2M
Margins
Gross margin20.6%
Operating margin-1244.6%
Net margin-1358.3%
FCF margin-1285.4%
Balance sheet
Total assets$42.1M
Total liabilities$23.7M
Total equity$18.5M
Cash & equivalents—
Long-term debt$12.2M
Cash flow
Operating cash flow-$32.7M
CapEx$0.00
Free cash flow-$43.7M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $3.4M, +14,6% YoY
- ▍Operating income +26,2% YoY
- ▍Net income +18,5% YoY
- ▍Free cash flow +20,2% YoY
- ▍Net margin -1358.3%
ANNUALFiled 2022-10-31
FY 2022 · Full-year highlights
Revenue $3.0M, +99,2% YoY; Operating income −67,4% YoY.
Revenue$3.0M+99,2 % YoY
Operating income-$57.4M−67,4 % YoY
Net income-$56.7M−83,0 % YoY
Free cash flow-$54.8M−79,9 % YoY
EPS—
Operating cash flow-$45.7M−85,7 % YoY
Financials
Income statement
Revenue$3.0M
Gross profit$918.0k
Operating income-$57.4M
Net income-$56.7M
Margins
Gross margin30.9%
Operating margin-1931.7%
Net margin-1910.2%
FCF margin-1846.2%
Balance sheet
Total assets$63.3M
Total liabilities$20.1M
Total equity$43.2M
Cash & equivalents—
Long-term debt$12.5M
Cash flow
Operating cash flow-$45.7M
CapEx-$694.0k
Free cash flow-$54.8M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $3.0M, +99,2% YoY
- ▍Operating income −67,4% YoY
- ▍Net income −83,0% YoY
- ▍Free cash flow −79,9% YoY
- ▍Net margin -1910.2%
ANNUALFiled 2021-10-21
FY 2021 · Full-year highlights
Revenue $1.5M; Operating income -$34.3M.
Revenue$1.5M
Operating income-$34.3M
Net income-$31.0M
Free cash flow-$30.5M
EPS—
Operating cash flow-$24.6M
Financials
Income statement
Revenue$1.5M
Gross profit$687.0k
Operating income-$34.3M
Net income-$31.0M
Margins
Gross margin46.1%
Operating margin-2298.4%
Net margin-2079.8%
FCF margin-2044.5%
Balance sheet
Total assets$102.6M
Total liabilities$7.5M
Total equity$95.1M
Cash & equivalents—
Long-term debt$266.0k
Cash flow
Operating cash flow-$24.6M
CapEx-$1.6M
Free cash flow-$30.5M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $1.5M
- ▍Operating income -$34.3M
- ▍Net margin -2079.8%
Valuation FY
Market price
$2,80
Market cap
$786.6M
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
—
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
— missing data
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskUnknown
Benchmarks vs cohort
No cohort benchmark data available for this issuer yet.
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 3 363 808 sh10 grants7 insiders
- Director · Series C Convertible Preferred Stock → Common StockAcquired 2 476 338 @ $2,90grant · 2026-06-11
- Director · Warrant → Common StockAcquired 619 084 @ $2,90grant · 2026-06-11
- Director · Stock Option → Common StockAcquired 80 000 @ $0,27grant · 2025-12-22
- Director, 10% owner · Stock Option → Common StockAcquired 80 000 @ $0,27grant · 2025-12-22
- Director · Stock Option → Common StockAcquired 80 000 @ $0,27grant · 2025-12-22
- Director · Stock Option → Common StockAcquired 80 000 @ $0,27grant · 2025-12-22
- Director · Stock Option → Common StockAcquired 80 000 @ $0,27grant · 2025-12-22
- Director, 10% owner · Series A Convertible Preferred Stock → Common StockDisposed 1 125 570conversion · 2025-10-13
- Director, 10% owner · Series A Convertible Preferred Stock → Common StockDisposed 1 151 346conversion · 2025-10-13
- Director, 10% owner · Series A Convertible Preferred Stock → Common StockDisposed 1 090 002conversion · 2025-10-13
- Director, 10% owner · Series A Convertible Preferred Stock → Common StockAcquired 1 094 567grant · 2025-09-29
- Director, 10% owner · Series A Convertible Preferred Stock → Common StockAcquired 1 060 489grant · 2025-09-29
- Director, 10% owner · Series A Convertible Preferred Stock → Common StockAcquired 1 080 248grant · 2025-09-29
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- Renalytix PLC Market data — financials · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
Insider activity
Mixed / flat0 buys · 0 sellsnet $03 insiders · last 365d
- Director, 10% owner · Common StockOther 1 090 002 · 2025-10-13
- Director, 10% owner · Common StockOther 1 125 570 · 2025-10-13
- Director, 10% owner · Common StockOther 1 151 346 · 2025-10-13
- Director, 10% owner · Series A Convertible Preferred StockOther 485 766 · 2025-09-29
- Director, 10% owner · Series A Convertible Preferred StockOther 422 835 · 2025-09-29
- Director, 10% owner · Series A Convertible Preferred StockOther 377 225 · 2025-09-29
Short positioning
31.7Kshares short-13.8% vs prior
1days to cover
31.6%short of daily vol
249fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
RENX.LCanonical
London Stock Exchange · GBp
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskUnknown
Evidence & claims
From filings & derived data- Gross margin (FY 2025-12-31): 29.1%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -79.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -89.8%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 3,091.3%Derived (calculated)
- Return on assets (FY 2025-12-31): -45.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.12xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 103,765.8%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 9,505.1%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 449.6%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 178.2%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 3,860.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 161.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
- Net margin (FY 2025-12-31): -194.1%Derived (calculated)
- Total assets (annual): USD 35.48MSEC XBRL filing
- Gross profit (annual): USD 2.39MSEC XBRL filing
- Long-term debt (annual): USD 8.24MSEC XBRL filing
- Total operating expenses (annual): USD 14.84MSEC XBRL filing
- Operating income (annual): USD -12.45MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -84SEC XBRL filing
- Net income (annual): USD -15.96MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -84SEC XBRL filing
- Current assets (annual): USD 2.57MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-08 04:39 UTCFILINGMaterial 8-K
2026-06-11 00:00 UTCINSIDER2 insider transactions — 2026-06 2 derivative
2026-06-11INSIDERBorg Bjarne Erik Siwert acquired 619.1k sh Warrant — Director
2026-06-11INSIDERBorg Bjarne Erik Siwert acquired 7.2k sh Series C Convertible Preferred Stock — Director
2025-12-22 00:00 UTCINSIDER5 insider transactions — 2025-12 5 derivative
2025-12-22INSIDERTweedy Jeffrey C. acquired 80.0k sh Stock Option — Director
2025-12-22INSIDERBorg Bjarne Erik Siwert acquired 80.0k sh Stock Option — Director, 10% owner
2025-12-22INSIDERDeMaria Peter G. acquired 80.0k sh Stock Option — Director
2025-12-22INSIDERMagrane J. Scott acquired 80.0k sh Stock Option — Director
2025-12-22INSIDERMelton Christopher acquired 80.0k sh Stock Option — Director
2025-10-13 00:00 UTCINSIDER6 insider transactions — 2025-10 3 derivative
2025-10-13INSIDERBorg Bjarne Erik Siwert transacted 1.09M sh — Director, 10% owner
2025-10-13INSIDERCialone Anthony M. transacted 1.13M sh — Director, 10% owner
2025-10-13INSIDERBurnham James D transacted 1.15M sh — Director, 10% owner
2025-10-13INSIDERCialone Anthony M. disposed of 187.6k sh Series A Convertible Preferred Stock — Director, 10% owner
2025-10-13INSIDERBorg Bjarne Erik Siwert disposed of 181.7k sh Series A Convertible Preferred Stock — Director, 10% owner
2025-10-13INSIDERBurnham James D disposed of 191.9k sh Series A Convertible Preferred Stock — Director, 10% owner
2025-09-29 00:00 UTCINSIDER6 insider transactions — 2025-09 3 derivative
2025-09-29INSIDERBorg Bjarne Erik Siwert transacted 485.8k sh Series A Convertible Preferred Stock — Director, 10% owner
2025-09-29INSIDERCialone Anthony M. transacted 422.8k sh Series A Convertible Preferred Stock — Director, 10% owner
2025-09-29INSIDERBurnham James D transacted 377.2k sh Series A Convertible Preferred Stock — Director, 10% owner
2025-09-29INSIDERBurnham James D acquired 377.2k sh Series A Convertible Preferred Stock — Director, 10% owner
2025-09-29INSIDERBorg Bjarne Erik Siwert acquired 485.8k sh Series A Convertible Preferred Stock — Director, 10% owner
2025-09-29INSIDERCialone Anthony M. acquired 422.8k sh Series A Convertible Preferred Stock — Director, 10% owner
2024-10-01 00:00 UTCINSIDER4 insider transactions — 2024-10
2024-09-10 00:00 UTCINSIDER2 insider transactions — 2024-09
2024-05-20 00:00 UTCINSIDER5 insider transactions — 2024-05
Showing the 40 most recent of 43 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage